A large number of dogs suffer from osteoarthritis (OA), a chronic, progressive and painful disease with a prevalence of up to 80 per cent in older canines (1). However, finding effective treatments remains a major challenge in veterinary medicine, as traditional therapies are often limited to pain management and carry the risk of side-effects. That's why an increasing number of studies are looking at nutritional supplements with no adverse effects, such as our PETAGILE® Bioactive Collagen Peptides (BCP®).
Treatment options
Typical signs of OA include stiffness, lameness and unwillingness to exercise, jump or climb (2). The disease progresses with the loss of articular cartilage within the synovial joints, leading to subchondral sclerosis, synovitis and thickening of the capsule (3).
Non-surgical, pain management solutions can alleviate symptoms but do not treat the cause. Non-steroidal anti-inflammatory drugs (NSAIDs), meanwhile, are widely used for their anti-inflammatory and analgesic effects, but are associated with gastrointestinal problems, renal failure, anorexia, lethargy and even death (4). So, in a bid to test the efficacy of an alternative treatment, a recent study investigated the role Bioactive Collagen Peptides (BCP®) could potentially play in the management of OA in dogs.